Top Celecoxib Brands Worth Considering

Celecoxib, a nonsteroidal anti-inflammatory drug (NSAID), is widely used to alleviate pain and inflammation associated with various conditions such as arthritis. With its popularity, several pharmaceutical companies have produced their own versions of this medication, each offering unique formulations and competitive pricing. Choosing the right brand can make a significant difference in terms of effectiveness and cost-efficiency for patients. To help you navigate through the various options, we have compiled a comprehensive list of the best celecoxib brands available on the market below.

Illustration of celecoxib

Best brands of celecoxib in 2025

Celebrex

Celebrex, the flagship brand of Pfizer Inc., is a leading producer of celecoxib, dominating the global market with over 80% of the revenue share in the oral capsules segment as of 2020. This brand has maintained its market leadership through strong brand recognition, extensive physician education, and patient support programs. Despite the entry of generic versions after the patent expiration in 2014, Celebrex continues to be a preferred choice due to its effectiveness and patient compliance. North America, particularly the United States, accounts for over 40% of the global revenue share, driven by high prescription volumes and favorable reimbursement policies. The brand's market position is further strengthened by Pfizer's investments in novel formulations and indications.

Elyxyb

Elyxyb, developed by Scilex Holding Company, is the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine with or without aura in adults. It contains the active ingredient celecoxib, a nonsteroidal anti-inflammatory drug (NSAID) with COX-2 selectivity, offering fast and long-lasting relief, with pain relief in as little as 15 minutes and significant relief compared to placebo within 45 minutes in nearly 50% of patients. Approximately 36% of patients were pain-free at two hours. Launched in April 2023, Elyxyb is positioned as a non-opioid alternative with potentially lower gastrointestinal side effects. The U.S. oral migraine drug market, where Elyxyb operates, was estimated at $1.8 billion in 2022. For more detailed information, visit this comprehensive resource.

Zydus

Zydus Lifesciences is a prominent producer of celecoxib, having launched the drug under the brand name Zycel, which has been a blockbuster molecule since its introduction. The company, ranked as one of the fastest-growing pharmaceutical companies in India, has a strong presence in the global market. Zydus Cadila's technical collaborations and innovative product launches have contributed significantly to its market share. For instance, the company was the first to launch several key drugs in India, including celecoxib, which has been well-received for its efficacy in managing pain and inflammation. With a robust manufacturing and distribution network, Zydus continues to expand its market reach. For more information about the company's history and growth, visit Zydus Lifesciences on Moneycontrol.

Lupin

Lupin, one of the world's leading generic pharmaceutical companies, is renowned for its high-quality celecoxib products. As the 10th largest generic pharma company globally, Lupin has a footprint across over 100 countries and operates 15 state-of-the-art manufacturing facilities that adhere to international standards. The company has played a significant role in reducing disease burden by providing affordable medicines, with over 70% of its products in the US ranking among the top three in their respective segments. Lupin's celecoxib, marketed as LUPIN-CELECOXIB, is bioequivalent to the reference listed drug (RLD) and is available in various strengths, including 50 mg, 100 mg, 200 mg, and 400 mg capsules. The company's commitment to quality and innovation ensures reliable and effective treatment options for patients worldwide.

Teva

Teva Pharmaceutical Industries Ltd. is a leading global producer known for its high-quality and affordable generic versions of celecoxib. In 2014, Teva settled patent litigation with Pfizer, allowing it to launch its generic versions of Celebrex(r) (celecoxib) in the United States, with tentative FDA approval for all strengths. As the world's leading generic drug maker, Teva boasts a global product portfolio of over 1,000 molecules and maintains a direct presence in approximately 60 countries. The company's branded businesses focus on various therapeutic areas, including pain management, employing around 45,000 people worldwide. Teva's net revenues reached $20.3 billion in 2013, underscoring its significant influence within the pharmaceutical industry.

Apotex

Apotex is a leading producer of celecoxib, offering high-quality capsules that are bioequivalent to the branded version, Celebrex^®. Their celecoxib capsules are available in various strengths, including 50mg and 100mg, and are latex, sugar, dye, and alcohol free, ensuring broad patient compatibility. Apotex's celecoxib products are part of the dominant oral capsules segment, which accounts for over 80% of the global celecoxib market revenue. The company's strong presence in the generic market helps meet the increasing demand for effective and safe pain management solutions, particularly for conditions like osteoarthritis and rheumatoid arthritis. With a focus on expanding geographic reach and improving manufacturing capabilities, Apotex remains a significant player in the celecoxib market. For more information, visit their celecoxib product page.

Dr. Reddy's

Dr. Reddy's Laboratories is a prominent producer of celecoxib, known for its high-quality formulations. The company's celecoxib oral solution, ELYXYB, has been approved by the FDA and is recognized for its efficacy in treating migraine and other pain conditions. In 2022, Dr. Reddy's experienced a 34% year-over-year growth in revenues from proprietary products, including ELYXYB, following the sale of U.S. and Canada territory rights to BioDelivery Sciences International, Inc. ELYXYB has been added to the preferred drug list of Indiana Medicaid, highlighting its acceptance in the market. The product's manufacturing has been scaled up to meet the rising demand for this rapid onset pain management regimen. For detailed insights, you can refer to their earnings release.

Mylan

Mylan is a prominent player in the celecoxib market, known for its high-quality and cost-effective generic versions of the drug. Mylan's celecoxib products have gained significant market share, particularly after the patent expiration of the branded version, Celebrex, in 2014. The company's strong manufacturing and supply chain capabilities have enabled it to expand its geographic reach and cater to a wide range of customers. Mylan's celecoxib capsules are preferred for their ease of administration and patient compliance, contributing to the segment's dominance, which accounts for over 80% of the global revenue share. Mylan's presence in the market has been instrumental in driving the growth of the celecoxib market, expected to exhibit a CAGR of 8.7% to 8.8% from 2024 to 2032/2033. For more information, visit Mylan's official website.

Sun Pharma

Sun Pharma, one of the leading generic pharmaceutical companies globally, is a prominent producer of celecoxib, a selective COX-2 inhibitor used to treat various conditions including osteoarthritis, rheumatoid arthritis, and acute pain. Founded in 1983, Sun Pharma has grown to become the fourth largest specialty generic pharmaceutical company in the world, with global revenues of US$ 5.4 billion. The company invests up to 6-8% of its global revenues into Research and Development (R&D) annually, ensuring high-quality and technologically complex products. Sun Pharma's extensive portfolio includes over 2000 high-quality molecules, and it sells over 30 billion doses annually across multiple therapeutic areas. With a strong presence in over 100 countries, Sun Pharma is recognized for its commitment to providing affordable and valued medicines.

Glenmark

Glenmark Pharmaceuticals is a prominent player in the Indian pharmaceutical market, with a significant coverage of over 35% as of the financial year 2020. The company has demonstrated its capability in producing high-quality medications, including celecoxib, a selective COX-2 inhibitor. Glenmark's strong market presence and regulatory approvals, such as the ANDA approval for various formulations, underscore its commitment to delivering effective treatments. The global celecoxib market, projected to reach USD 3.1 billion by 2032 with a CAGR of 8.7%, highlights the growing demand for such medications, which Glenmark is well-positioned to meet. With its robust financial performance, including a 6.9% consolidated revenue growth and an 18.1% EBITDA margin in Q1 FY 2024-25, Glenmark continues to be a reliable producer of celecoxib. For more detailed financial insights, visit their investors page.